Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28663627 | 0.96 | CA5A (0.40) | TSHRCA5ACA5BCA1CA2 | |
| SCHEMBL3080703 | 0.78 | — | — | |
| SCHEMBL27816215 | 0.72 | — | — | |
| SCHEMBL29895058 | 0.72 | — | — | |
| Sulfuric Acid SCHEMBL28011354 | 0.67 | CA5A (0.50) | TSHRCA5ACA5BCA1CA2 | |
| Sulfuric Acid SCHEMBL11314356 | 0.67 | — | — | |
| SCHEMBL29079969 | 0.64 | — | — | |
| SCHEMBL6890356 | 0.64 | CA5A (0.46) | TSHRCA5ACA5BCA1CA2 | |
| Sulfuric Acid SCHEMBL8612638 | 0.61 | CA5A (0.75) | TSHRCA5ACA5BCA1CA2 | |
| Sulfuric Acid SCHEMBL8595596 | 0.61 | CA5A (0.75) | TSHRCA5ACA5BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109942001-B | Silicon negative electrode material with spherical thorn-shaped structure and preparation method thereof | 骆驼集团武汉光谷研发中心有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-1070049-B1 | BENZAMIDE AND SULFONAMIDE SUBSTITUTED AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2004-06-30 | — | — | EP | claimed |
| US-6730783-B2 | REACTING AMINOGUANIDINE WITH CARBONYL COMPOUND TO FORM AMIDINOHYDRAZONE; REDUCTION; REACTING WITH ALKOXYAMINE; GUANIDINYLATION; ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-6706765-B2 | ESPECIALLY TRYPSIN-LIKE SERINE PROTEASES, SUCH AS CHYMOTRYPSIN, TRYPSIN, THROMBIN, PLASMIN AND FACTOR XA. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-03-16 | — | — | US | claimed |
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-01 | — | — | US | claimed |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | claimed |
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | claimed |
| EP-1073449-A4 | AMINO ACID AMIDINOHYDRAZONES, ALKOXYGUANIDINES AND AMINOGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2003-01-02 | — | — | EP | claimed |
| US-6486174-B2 | TREATMENT OF TUMOR GROWTH, METASTASIS, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS, SICKLE CELL ANEMIA, NERVE SYSTEM DISORDERS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-26 | — | — | US | claimed |
| US-6417161-B1 | KETONE AMINO DERIVATIVES | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-07-09 | — | — | US | claimed |
| US-6344466-B2 | ANTITHROMBOTIC ACTIVITY, USE IN INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS INC. | 2002-02-05 | — | — | US | claimed |
| US-6344484-B1 | TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | claimed |
| EP-1159262-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | claimed |
| US-20010031870-A1 | Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors | SOLL RICHARD M (US) | 2001-10-18 | — | — | US | claimed |
| US-6235778-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | claimed |
| EP-1073449-A1 | AMINO ACID AMIDINOHYDRAZONES, ALKOXYGUANIDINES AND AMINOGUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | claimed |
| WO-2000047552-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| WO-1999055355-A1 | AMINO ACID AMIDINOHYDRAZONES, ALKOXYGUANIDINES AND AMINOGUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-11-04 | — | — | WO | claimed |
| US-4039483-A | Method of producing an ion exchanger by reacting unsaturated vulcanized or powdered rubbers with iodine isocyanate and then introducing ion exchange groups by further reaction | BRIDGESTONE TIRE COMPANY LIMITED (JA) | 1977-08-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | TSHR 579/4885CA5A 4180/4885CA5B 3321/4885 |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | PLG, MMP9, F9 | TSHR 577/4885CA5A 4179/4885CA5B 3404/4885 |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | TSHR 685/4885CA5A 3881/4885CA5B 2926/4885 |
| US-20010031870-A1 | Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors | PLG, F9, TFPI | TSHR 1246/4885CA5A 2088/4885CA5B 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.